antibodies

Datasheet for ABIN3021978 anti-Coagulation Factor X antibody (AA 235-488)






Overview

Quantity:	100 µL
Target:	Coagulation Factor X (F10)
Binding Specificity:	AA 235-488
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This Coagulation Factor X antibody is un-conjugated
Application:	Western Blotting (WB), Immunofluorescence (IF)
Product Details	
Immunogen:	Recombinant fusion protein containing a sequence corresponding to amino acids 235-488 of human F10 (NP_000495.1).
Immunogen:	human F10 (NP_000495.1). IVGGQECKDG ECPWQALLIN EENEGFCGGT ILSEFYILTA AHCLYQAKRF KVRVGDRNTE QEEGGEAVHE VEVVIKHNRF TKETYDFDIA VLRLKTPITF RMNVAPACLP ERDWAESTLM TQKTGIVSGF GRTHEKGRQS TRLKMLEVPY VDRNSCKLSS SFIITQNMFC AGYDTKQEDA CQGDSGGPHV TRFKDTYFVT GIVSWGEGCA RKGKYGIYTK VTAFLKWIDR SMKTRGLPKA
Immunogen: Sequence:	human F10 (NP_000495.1). IVGGQECKDG ECPWQALLIN EENEGFCGGT ILSEFYILTA AHCLYQAKRF KVRVGDRNTE QEEGGEAVHE VEVVIKHNRF TKETYDFDIA VLRLKTPITF RMNVAPACLP ERDWAESTLM TQKTGIVSGF GRTHEKGRQS TRLKMLEVPY VDRNSCKLSS SFIITQNMFC AGYDTKQEDA CQGDSGGPHV TRFKDTYFVT GIVSWGEGCA RKGKYGIYTK VTAFLKWIDR SMKTRGLPKA KSHAPEVITS SPLK
Immunogen: Sequence: Isotype:	human F10 (NP_000495.1). IVGGQECKDG ECPWQALLIN EENEGFCGGT ILSEFYILTA AHCLYQAKRF KVRVGDRNTE QEEGGEAVHE VEVVIKHNRF TKETYDFDIA VLRLKTPITF RMNVAPACLP ERDWAESTLM TQKTGIVSGF GRTHEKGRQS TRLKMLEVPY VDRNSCKLSS SFIITQNMFC AGYDTKQEDA CQGDSGGPHV TRFKDTYFVT GIVSWGEGCA RKGKYGIYTK VTAFLKWIDR SMKTRGLPKA KSHAPEVITS SPLK IgG

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/3 | Product datasheet for ABIN3021978 | 09/11/2023 | Copyright antibodies-online. All rights reserved.

Alternative Name: Background:	Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple
Background:	cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds, the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing
	to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds, the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing
	held together by 1 or more disulfide bonds, the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing
	other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing
	activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing
	pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing
	Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing
	deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing
	transcript variants encoding different isoforms that may undergo similar proteolytic processing
	to generate mature polypeptides.,F10,FX,FXA,Cardiovascular,Blood,Coagulation,F10
Molecular Weight:	54 kDa
Gene ID:	2159
UniProt:	P00742
Application Details	
Application Notes:	WB,1:500 - 1:2000,IF,1:10 - 1:100
Restrictions:	For Research Use only
Handling	
Format:	Liquid
Buffer:	PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which
	should be handled by trained staff only.
Handling Advice:	Avoid freeze / thaw cycles
Storage:	-20 °C
Storage Comment:	Store at -20°C. Avoid freeze / thaw cycles.

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 2/3 | Product datasheet for ABIN3021978 | 09/11/2023 | Copyright antibodies-online. All rights reserved.



Western Blotting

Image 1. Western blot analysis of extracts of various cell lines, using F10 antibody.

Immunofluorescence

Image 2. Immunofluorescence analysis of A549 cell using F10 antibody. Blue: DAPI for nuclear staining.

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 3/3 | Product datasheet for ABIN3021978 | 09/11/2023 | Copyright antibodies-online. All rights reserved.